Marshall Wace
VKTX icon

Marshall Wace’s Viking Therapeutics VKTX Stock Holding History

Marshall Wace’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.67M Sell
42,767
-47,593
-53% -$1.54M ﹤0.01% 1949
2026
Q1 		$2.94M Buy
+90,360
New +$2.9M ﹤0.01% 1579
2025
Q2 		– Sell
-207,873
Closed -$5.02M – 3215
2025
Q1 		$5.02M Buy
207,873
+187,759
+933% +$5.93M 0.01% 1064
2024
Q4 		$809K Buy
20,114
+2,256
+13% +$129K ﹤0.01% 1829
2024
Q3 		$1.13M Sell
17,858
-55,842
-76% -$3.28M ﹤0.01% 1605
2024
Q2 		$3.91M Sell
73,700
-297,986
-80% -$19.5M 0.01% 1105
2024
Q1 		$30.5M Buy
371,686
+268,831
+261% +$12M 0.05% 373
2023
Q4 		$1.91M Buy
102,855
+50,297
+96% +$658K ﹤0.01% 1236
2023
Q3 		$582K Sell
52,558
-80,632
-61% -$1.15M ﹤0.01% 1669
2023
Q2 		$2.16M Buy
133,190
+48,467
+57% +$1.02M ﹤0.01% 1365
2023
Q1 		$1.41M Buy
84,723
+14,388
+20% +$149K ﹤0.01% 1647
2022
Q4 		$661K Sell
70,335
-1,267,045
-95% -$5.66M ﹤0.01% 2259
2022
Q3 		$3.64M Buy
+1,337,380
New +$4.38M 0.01% 1612

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Marshall Wace's VKTX Position: Q2 2026 in Review

Marshall Wace reduced its Viking Therapeutics (VKTX) stake by 53% in Q2 2026, selling an estimated $1.54M and leaving 42,767 shares worth $1.67M. The position accounts for ﹤0.01% of the portfolio, ranked #1949.

Marshall Wace first reported a position in VKTX in Q3 2022 and has held it in 13 quarters since. The position peaked at $30.5M in Q1 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Marshall Wace held 42,767 shares of Viking Therapeutics worth $1.67M as of Q2 2026.
  • Marshall Wace sold 47,593 Viking Therapeutics shares in Q2 2026, an estimated $1.54M.
  • Viking Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1949 holding.
  • Marshall Wace first reported a position in Viking Therapeutics in Q3 2022 and has held it in 13 quarters since.
  • Marshall Wace's Viking Therapeutics position peaked at $30.5M in Q1 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.